2021-06-06-世界卫生组织-GLASS_2020_White_paper_–_Workstream_2_–_AMR_surveillance_2页_720kb

Summary of Workstream 2: AMR Surveillance

Individual Data Reporting

GLASS-AMR allows submission of anonymized individual AMR data to improve monitoring, analysis, and risk factor identification. Feedback shows 51% of countries can participate, with limitations including lab systems, resources, and stakeholder engagement cited by others; discussions focus on overcoming challenges and WHO support.

Inclusion of Molecular Markers

GLASS-AMR includes molecular AMR diagnostic data to better understand resistance mechanisms, such as specific markers for pathogens like Acinetobacter spp. and E. coli. Countries currently use molecular methods, but challenges remain, particularly in low-middle income countries; discussions address WHO's role in standardization.

Improving Data Quality and Representativeness

Current AMR surveillance based on routine clinical data has limitations in resource-limited settings, such as sampling issues and incomplete coverage. GLASS is developing protocols and exploring alternative methods like syndrome-based and population-based surveillance; key discussions include implementation steps and WHO support for enhancement.